Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Debiopharm, Shasun announce licensing deal
May 2013
SHARING OPTIONS:

LAUSANNE, SwitzerlandóShasun Pharmaceuticals Ltd. has begun a licensing agreement with Debiopharm Group to manufacture and commercialize Huperzine-A, a potent and reversible acetylcholinesterase inhibitor with demonstrated promise in treating Alzheimer's disease patients. Per the terms of the agreement, Shasun will have access to Debiopharm's technology to manufacture synthetic Huperzine-A under GMP- quality conditions and commercialize it in pharmaceutical and nutraceutical markets. Financial details were not disclosed.  
 
"We are delighted to continue our collaboration with Shasun Pharmaceuticals Ltd. Clinical studies have demonstrated the drug to enable significant improvement in both memory deficit and cognitive performance, and we are excited to have the opportunity to add value to this technology while contributing to improve people's quality of life," said Dr. Rolland-Yves Mauvernay, president and founder of Debiopharm.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.